Short Interest in Invesco Biotechnology & Genome ETF (NYSEARCA:PBE) Expands By 23.3%

Invesco Biotechnology & Genome ETF (NYSEARCA:PBE) was the target of a large growth in short interest in December. As of December 31st, there was short interest totaling 27,309 shares, a growth of 23.3% from the December 15th total of 22,155 shares. Based on an average daily volume of 8,216 shares, the days-to-cover ratio is currently 3.3 days. Approximately 0.9% of the shares of the company are sold short. Approximately 0.9% of the shares of the company are sold short. Based on an average daily volume of 8,216 shares, the days-to-cover ratio is currently 3.3 days.

Invesco Biotechnology & Genome ETF Trading Down 1.3%

Shares of PBE stock opened at $80.91 on Monday. The stock has a market cap of $258.10 million, a P/E ratio of 20.44 and a beta of 0.79. Invesco Biotechnology & Genome ETF has a 1 year low of $54.52 and a 1 year high of $85.73. The stock has a 50 day simple moving average of $81.38 and a 200 day simple moving average of $73.54.

Institutional Trading of Invesco Biotechnology & Genome ETF

Several large investors have recently modified their holdings of PBE. Royal Bank of Canada increased its position in shares of Invesco Biotechnology & Genome ETF by 22.3% in the first quarter. Royal Bank of Canada now owns 75,402 shares of the company’s stock worth $4,783,000 after purchasing an additional 13,767 shares during the period. Goldman Sachs Group Inc. grew its stake in Invesco Biotechnology & Genome ETF by 5.9% during the first quarter. Goldman Sachs Group Inc. now owns 37,657 shares of the company’s stock worth $2,389,000 after buying an additional 2,103 shares in the last quarter. Signet Financial Management LLC increased its holdings in Invesco Biotechnology & Genome ETF by 3.9% in the 2nd quarter. Signet Financial Management LLC now owns 4,351 shares of the company’s stock valued at $279,000 after buying an additional 164 shares during the period. Massachusetts Wealth Management raised its position in shares of Invesco Biotechnology & Genome ETF by 1.0% in the 2nd quarter. Massachusetts Wealth Management now owns 18,394 shares of the company’s stock valued at $1,179,000 after buying an additional 190 shares in the last quarter. Finally, RFG Advisory LLC bought a new stake in shares of Invesco Biotechnology & Genome ETF during the 2nd quarter worth approximately $300,000.

Invesco Biotechnology & Genome ETF Company Profile

PowerShares Dynamic Biotechnology & Genome Portfolio (the Fund) is based on the Dynamic Biotechnology & Genome Intellidex Index (the Index). The Fund seeks investment results that correspond generally to the price and yield of the Index. The Index consists of stocks of 30 the United States biotechnology and genome companies. The Fund will normally invest at least 90% of its total assets in common stocks that consists of the Index. The Index is designed to provide capital appreciation by evaluating companies based on a variety of investment merit criteria, including fundamental growth, stock valuation, investment timeliness and risk factors.